Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.030 -0.010 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! 
Via InvestorPlace
Analyst Expectations for Esperion Therapeutics's Future
Via Benzinga
5 Analysts Have This to Say About Esperion Therapeutics
Via Benzinga
Analyst Expectations for Esperion Therapeutics's Future
Via Benzinga
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Third Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
"CLEAR" Progress At Esperion
Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights. 
Via Talk Markets
American College of Cardiology Program to Increase Cholesterol Screenings
From Esperion Therapeutics, Inc.; The American College of Cardiology
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Is Esperion Therapeutics Stock Trading Higher Today?
Esperion Therapeutics Inc (NASDAQ: ESPR) announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European  
Via Benzinga
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Second Quarter 2023 Financial Results on August 1
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed... 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.